Imaging Industry Wants A Rewrite On FDA Contrast Indication Guidance

An FDA draft guideline outlining the regulatory pathway for imaging equipment makers seeking to add new contrast agent indication labeling needs an overhaul to include more explicit guidance for sponsors, manufacturers say